News

Hosted on MSN2mon
Tempus AI Reverses 192% Run. Why At Least One Analyst Remains A Believer.
Tempus AI stock crashed Tuesday as investors questioned the medical AI company's long-term growth prospects. But William Blair analyst Andrew Brackmann remains a believer in the stock. Tempus uses ...
Nasdaq15d
Tempus to Report First Quarter 2025 Financial Results on May 6
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal ...
Business Wire10d
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study ...
Crain's Chicago Business7d
Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.
The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...